Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Next-generation of targeted AAVP vectors for systemic transgene delivery against cancer.

Suwan K, Yata T, Waramit S, Przystal JM, Stoneham CA, Bentayebi K, Asavarut P, Chongchai A, Pothachareon P, Lee KY, Topanurak S, Smith TL, Gelovani JG, Sidman RL, Pasqualini R, Arap W, Hajitou A.

Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18571-18577. doi: 10.1073/pnas.1906653116. Epub 2019 Aug 2.

2.

Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma.

Przystal JM, Waramit S, Pranjol MZI, Yan W, Chu G, Chongchai A, Samarth G, Olaciregui NG, Tabatabai G, Carcaboso AM, Aboagye EO, Suwan K, Hajitou A.

EMBO Mol Med. 2019 Apr;11(4). pii: e8492. doi: 10.15252/emmm.201708492.

3.

Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM.

Przystal JM, Hajji N, Khozoie C, Renziehausen A, Zeng Q, Abaitua F, Hajitou A, Suwan K, Want E, Bomalaski J, Szlosarek P, O'Neill K, Crook T, Syed N.

Cell Death Dis. 2018 Dec 13;9(12):1192. doi: 10.1038/s41419-018-1195-4.

4.

Dual systemic tumor targeting with ligand-directed phage and Grp78 promoter induces tumor regression.

Kia A, Przystal JM, Nianiaris N, Mazarakis ND, Mintz PJ, Hajitou A.

Mol Cancer Ther. 2012 Dec;11(12):2566-77. doi: 10.1158/1535-7163.MCT-12-0587. Epub 2012 Oct 10.

5.

Proteasome inhibition in cancer is associated with enhanced tumor targeting by the adeno-associated virus/phage.

Przystal JM, Umukoro E, Stoneham CA, Yata T, O'Neill K, Syed N, Hajitou A.

Mol Oncol. 2013 Feb;7(1):55-66. doi: 10.1016/j.molonc.2012.08.001. Epub 2012 Aug 21.

Supplemental Content

Loading ...
Support Center